under the radar.
NEW YORK, NY – October 26, 2015 -- InvestorsHub NewsWire -- Small Cap Street makes the connection between sophisticated investors and high quality micro and small cap companies that are currently undervalued. We are an issuer of reports written by experienced financial analysts and who provide a straight forward assessment of profiled companies. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.
*Special Situation Alert Coming Tuesday, October 27th, 2015*
Small Cap Street and several other large media providers will be profiling an exceptional growth company that has some similarities to our last 200% winner.
This company recently executed a large reverse merger and is flying way under the radar. With an extremely tiny float we are expecting this to be one of our best alerts ever.
Be ready at 9:45 am EST on Tuesday, October 27th, 2015 by joining our group here: smallcapstreet.com
To receive profiles in real time, text "Street" to 25827
4 Brief Company Reports -
Viropro, Inc. (OTCBB: VPRO) through its subsidiaries, is engaged in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. The company is also involved in the transfer of its proprietary technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases, such as cancer, diabetes, hepatitis, or multiple sclerosis.
VPRO has signed a non-binding Letter of Intent for the acquisition of NovaRx, a San pioneer in immuno-oncology, in an all-stock transaction that is expected to close by year-end. NovaRx has developed a method of activating the body's immune system to recognize and destroy cancer cells. In a Phase II trial, the company demonstrated a significant improvement in survival for patients with non-small cell lung cancer. A Phase III trial did not achieve its desired endpoint. The company's management believes that a properly designed and administered Phase III study will yield different results.
Kallo, Inc. (OTCQB: KALO) develops and delivers innovative, technologically advanced and turnkey healthcare solutions in the developing world and rural communities including infectious disease management, education and training programs. The company's mobile technology suite transforms the delivery of rural medicine, disease management, clinical globalization, and eHealth solutions.
KALO was recognized last month with the Frost & Sullivan 2015 Award for Emerging Market Innovation. This award recognizes Kallo's unique holistic approach to healthcare delivery. Kallo's modular approach caters to the specific healthcare needs of each region through a combination of polyclinics, mobile clinics, teaching institutions and telemedicine. This system is designed to serve such emerging nations as Guinea, Senegal, Nigeria, Peru, Brazil, Cameroon and Chad.
Urban Barns Foods Inc. (OTCQB: URBF) is a Canadian food producer growing fresh vegetables year round. Grown in a completely controlled environment, their vegetables are grown from non-GMO seeds and free of pesticide, herbicide, and fungicide. Controlled environment means no contact with the outside world, eliminating the possibilities of contamination and infection. The company specializes in leafy vegetables including lettuce and basil that are Kosher-certified.
URBF has undergone a restructuring of its executives this year making changes in the Chairman, CEO, and President and Directors positions. The company’s fiscal year ends July 31st. Recent financials indicate a drop in shareholder equity, primarily due to increased debt, and a better bottom line due to a significant cut in operating expenses.
AI
